Suppr超能文献

激素受体阳性和 HER2 阴性乳腺癌且淋巴结受累女性中孤立局部复发的模式和危险因素:PACS 01 和 PACS 04 试验的 10 年随访分析。

Pattern and risk factors of isolated local relapse among women with hormone receptor-positive and HER2-negative breast cancer and lymph node involvement: 10-year follow-up analysis of the PACS 01 and PACS 04 trials.

机构信息

Department of Cancer Medicine, University of Paris Saclay, Gustave Roussy, Villejuif, France.

BiostatisticsDepartment, Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France.

出版信息

Breast Cancer Res Treat. 2023 Jun;199(2):371-379. doi: 10.1007/s10549-023-06912-4. Epub 2023 Mar 29.

Abstract

PURPOSE

We aimed to determine the pattern of isolated local recurrences (ILR) in women with stage II-III hormone receptor-positive and human epidermal growth factor receptor 2 breast cancer (HR + /HER2-BC) after 10-year follow-up.

METHODS

UNICANCER-PACS 01 and PACS 04 trials included 5,008 women with T1-T3 and N1-N3 to evaluate the efficacy of different anthracycline ± taxanes-containing regimens after modified mastectomy or lumpectomy plus axillary lymph node dissection. We analyzed the data from 2,932 women with HR + /HER2- BC to evaluate the cumulative incidence of ILR and describe the factors associated with ILR.

RESULTS

After a median follow-up of 9.1 years (95% CI 9.0-9.2 years), the cumulative incidence of ILR increased steadily between 1 and 10 years from 0.2% to 2.5%. The multivariable analysis showed that older age (subhazard ratios [sHR] = 0.95, 95% CI 0.92-0.99) and mastectomy (sHR = 0.39, 95% CI 0.17-0.86) were associated with lower risk of ILR, and no adjuvant endocrine therapy (sHR = 2.73, 95% CI 1.32 7-5.67) with increased risk of ILR.

CONCLUSION

In this population of high-risk patients with localized HR + /HER2- BC, the risk of ILR was low but remained constant over 10 years. Younger age at diagnosis, breast-conserving surgery, and adjuvant endocrine therapy were independent risk factors of ILR.

摘要

目的

我们旨在确定激素受体阳性和人表皮生长因子受体 2 型乳腺癌(HR+/HER2-BC)女性在 10 年随访后孤立局部复发(ILR)的模式。

方法

UNICANCER-PACS 01 和 PACS 04 试验纳入了 5008 名 T1-T3 和 N1-N3 期患者,旨在评估改良乳房切除术或保乳术加腋窝淋巴结清扫术后不同蒽环类药物±紫杉烷类药物方案的疗效。我们分析了 2932 名 HR+/HER2-BC 女性的数据,以评估 ILR 的累积发生率,并描述与 ILR 相关的因素。

结果

中位随访 9.1 年(95%CI 9.0-9.2 年)后,1-10 年内 ILR 的累积发生率从 0.2%稳步上升至 2.5%。多变量分析显示,年龄较大(亚危险比[sHR] = 0.95,95%CI 0.92-0.99)和乳房切除术(sHR = 0.39,95%CI 0.17-0.86)与 ILR 风险降低相关,而无辅助内分泌治疗(sHR = 2.73,95%CI 1.32-5.67)与 ILR 风险增加相关。

结论

在该局部 HR+/HER2-BC 高危患者人群中,ILR 的风险较低,但在 10 年内保持不变。诊断时年龄较小、保乳手术和辅助内分泌治疗是 ILR 的独立危险因素。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验